CellaVision AB (publ)
CLVSF
Get informed when a big investor buys or sells
+ FollowMarket Cap$333.92M
Close$
$7.55
46% downside
Current Fair Value
46% downsideOvervalued by 46% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $333.92 Million |
|---|---|
| Enterprise Value | $215.03 Million |
| Dividend Yield | $0.30 (1.70%) |
| Earnings per Share | $6.42 |
| Beta | 0.87 |
| Outstanding Shares | 23,851,547 |
Return
| Return on Equity | 14.67% |
|---|---|
| Return on Assets | 11.38% |
| Return on Invested Capital | 16.43% |
Valuation & Multiples
| P/E Ratio | 29.91 |
|---|---|
| PEG | -213.96 |
| Price to Sales | 0.47 |
| Price to Book Ratio | 0.39 |
| Enterprise Value to Revenue | 0.29 |
| Enterprise Value to EBIT | 1.31 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0.24 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 17, 2026
EPS Estimate
$0.14
Average shareholder expectationRevenue Estimate
$18.91 M
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$0.14
Average shareholder expectationRevenue Estimate
$19.19 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About CellaVision AB (publ)
251 employees
CEO: Steve Ferguson CellaVision AB (publ), a Swedish enterprise established in 1994 and based in Lund, specializes in crafting and distributing advanced digital systems for analyzing blood and other bodily fluids within the healthcare industry. The company ...